Quick Takeaways
- Adimab, LLC filed SCHEDULE 13D/A for Invivyd, Inc. Common Stock, $0.0001 par value per share (IVVD).
- Disclosed ownership: 7.3%.
- Date of event: 23 Dec 2025.
Adimab, LLC - 23 Dec 2025 SCHEDULE 13D/A Report for Invivyd, Inc. Common Stock, $0.0001 par value per share (IVVD)
- Filing Manager
- Adimab, LLC
- Reporting Manager
- Adimab, LLC
- Symbol
- IVVD
- Shares outstanding
- 277,563,973 shares
- Disclosed Ownership
- 20,262,170 shares
- Ownership
- 7.3%
- Form type
- SCHEDULE 13D/A
- Filing time
- 29 Dec 2025, 16:15:02 UTC
- Date of event
- 23 Dec 2025
- Previous filing
- 19 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Adimab, LLC disclosed 7.3% ownership in Invivyd, Inc. Common Stock, $0.0001 par value per share (IVVD) on 23 Dec 2025."
What Changed
- Previous schedule filing date: 19 Nov 2025.
- Current filing was accepted on 29 Dec 2025, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Adimab, LLC | 7.3% | 20,262,170 | 20,262,170 | /s/ Philip Chase | Philip Chase, Chief Executive Officer | 0001545672 |